Results 141 to 150 of about 111,198 (373)

International collaborative study for the calibration of proposed International Standards for thromboplastin, rabbit, plain, and for thromboplastin, recombinant, human, plain

Journal of Thrombosis and Haemostasis, 2018
A. Besselaar, V. Chantarangkul, F. Angeloni, N. Binder, M. Byrne, R. Dauer, B. Gudmundsdottir, J. Jespersen, S. Kitchen, C. Legnani, T. Lindahl, R. Manning, M. Martinuzzo, O. Panes, V. Pengo, A. Riddell, S. Subramanian, A. Szederjesi, C. Tantanate, P. Herbel, A. Tripodi   +20 more
semanticscholar   +1 more source

Safety and Use of Eptacog Beta 225 µg/kg in Patients With Haemophilia A or B With Inhibitors

Haemophilia, EarlyView.
Introduction Eptacog beta is an activated recombinant human factor VII bypassing agent approved for treating bleeding episodes (BEs) in patients aged ≥12 years with haemophilia A or B with inhibitors. Two initial dose regimens (IDRs) of either 75 or 225 µg/kg, followed by 75 µg/kg, are approved.
Manuel Carcao, Cédric Hermans, Adam Giermasz, Craig Kessler, Wolfgang Miesbach, Doris Quon, Jerzy Windyga, Johnny Mahlangu   +7 more
wiley   +1 more source

Factor VII Padua 2: another factor VII abnormality with defective ox brain thromboplastin activation and a complex hereditary pattern [PDF]

, 1979
Antonio Girolami, G Cattarozzi, Renzo Dal Bo Zanon, F. Toffanin   +3 more
openalex   +1 more source

Investigation of sensitivity for coagulation factor deficiency in APTT and PT : how to perform it? [PDF]

, 2016
Devreese, Katrien, Dumoulin, Els, Fiers, Lisse   +2 more
core   +1 more source

Estimating the Factor VIII‐Equivalent Activity of Emicizumab Using Global Assays of Haemostasis

Haemophilia, EarlyView.
ABSTRACT Background Emicizumab is a bispecific monoclonal antibody mimicking factor (F) VIII activity and an effective therapy for prophylaxis in people with haemophilia A (PWHA). The FVIII‐equivalent activity (FVIIIeq) of emicizumab remains unknown. Objectives To estimate FVIIIeq of emicizumab using global assays of haemostasis.
Daniel Kraemmer, Cihan Ay, Judit Rejtő, Georg Heinze, Peter Quehenberger, Ingrid Pabinger, Oliver Königsbrügge   +6 more
wiley   +1 more source

Phospholipase C from Bacillus cereus and Its Use in Studies of Tissue Thromboplastin [PDF]

, 1972
Anne‐Brit Otnæss, Hans Prydz, Eirik Bjørklid, Åse Gladhaug Berre   +3 more
openalex   +1 more source

Effectiveness and safety of antithrombin for treatment of portal vein thrombosis: Nationwide prospective surveillance of 4 years of clinical experience in Japan

Hepatology Research, EarlyView.
Abstract Aim Antithrombin (AT), a plasma protein with anticoagulant properties, has a long‐standing medical history, primarily for treatment of congenital AT deficiency. Accumulated clinical experiences suggest AT is a potential anticoagulant for thrombotic diseases. This study aimed to clarify the effectiveness, safety, and clinical significance of AT
Shoichi Matsutani, Makoto Arakawa, Susumu Nakano   +2 more
wiley   +1 more source

The partial thromboplastin (cephalin) time test [PDF]

, 1972
L. Poller, J M Thomson
openalex   +1 more source

Risk Factors for Traumatic Lumbar Puncture in Children With ALL

Acta Paediatrica, EarlyView.
Sirkku Setänen, Arja Harila, Viola Metsistö, Christoffer Ehrstedt   +3 more
wiley   +1 more source

Measuring Direct Oral Anticoagulant (DOAC) Levels: Applications, Limitations, and Future Directions

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction There are important challenges with the measurement and interpretation of direct oral anticoagulant (DOAC) anticoagulant effect including a lack of therapeutic ranges, inaccuracy of routinely available coagulation assays, lack of established thresholds for clinically significant effect, and uncertainty about how to apply the ...
Siraj Mithoowani, Chee Wee Tan, Deborah M. Siegal   +2 more
wiley   +1 more source